Cystic Fibrosis Trust responds to expansion of NHS AMR pilot

Lucy Allen, Director of Research and Healthcare Data at Cystic Fibrosis Trust said: "We're pleased to see the NHS prioritising the development of new antibiotics, as for people with cystic fibrosis, antimicrobial resistance (AMR) can be a matter of life and death. People with CF often suffer from chronic and acute lung infections, managed by antibiotic treatment. Antimicrobial resistance makes these infections very difficult to treat and infections can be devastating.



"We will be submitting evidence to the consultation in the coming weeks, drawing on the CF AMR Syndicate, of which we are a leading partner, which aims to speed up the discovery process for new antimicrobial drugs. The expansion of this NHS pilot is an important step to stop CF damaging and shortening lives and ensure everyone with the condition can live a life unlimited."